BackTitan Medical Overview

Titan Medical EBIT

Titan Medical's EBIT is $-4.9M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.03M
↓ 107.39% YoY

As of Jun 30, 2024

Annual EBIT (TTM)

-$4.87M
↑ 55.45% YoY

Trailing 12 months ending Jun 30, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Titan Medical (TMD.TO) FAQ

The latest EBIT for TMD.TO is $-4.9M as of June 2024. That compares with $-11M in the prior-year period — up 55.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Titan Medical's historical trend and sector peers before judging valuation or financial health.

Over the past year, TMD.TO's EBIT moved from $-11M to $-4.9M — a 55.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Titan Medical's operating scale or balance-sheet position.

Against Healthcare companies, TMD.TO currently prints $-4.9M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Titan Medical's growth, margins, and balance sheet.

A EBIT figure of $-4.9M for TMD.TO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting TMD.TO's EBIT ($-4.9M), review year-over-year change from $-11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.